Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Top French Advisor Resigns Amid Drug Industry Scandal

By Drug Discovery Trends Editor | April 18, 2014

In this Wednesday, May 9, 2012 file photo, Francois Hollande's political adviser Aquilino Morelle smiles as he walks to a meeting of the Socialist group at the National Assembly in Paris. The French president’s top adviser has resigned following allegations of a past conflict of interest, striking a new blow to already unpopular Francois Hollande. Aquilino Morelle - Hollande’s political adviser and head of communication staff - announced his resignation Friday, an official in president’s office said. Morelle has denied allegations by news website Mediapart of a conflict of interest while he worked for the government pharmaceutical regulator in 2007, while also lobbying for the drug industry. The report also criticized Morelle’s supposed lavish lifestyle at a time when the government is making harsh cuts in public spending. Hollande’s approval rating has recently hit a new low of 18% despite a cabinet reshuffle three weeks ago. (AP Photo/Thibault Camus, file)The French president’s top adviser resigned Friday following allegations of a past conflict of interest, striking a new blow to the already unpopular Francois Hollande.
 
Aquilino Morelle — Hollande’s political adviser and head of his communication staff — had denied allegations by the news website Mediapart that he worked for the government pharmaceutical regulator in 2007 while also lobbying for the drug industry.
 
The report also criticized Morelle’s supposed lavish lifestyle at a time when the government is making cuts in public spending.
 
Hollande sought to distance himself from the new scandal, telling reporters while on a visit to Clermont-Ferrand “I am not the judge of what he did before.”
 
“What happened before, it’s up to him alone to answer for,” Hollande said, adding that he’d accepted Morelle’s resignation “immediately.”
 
Hollande’s approval rating has recently hit a new low of 18% despite a cabinet reshuffle three weeks ago.
 
Date: April 18, 2014
Source: Associated Press

Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE